மான்டஸ் ஆர்க்கிமிடீஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மான்டஸ் ஆர்க்கிமிடீஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மான்டஸ் ஆர்க்கிமிடீஸ் Today - Breaking & Trending Today

Warren Buffett Piles on SPACs and CF Finance Lowers Deal Valuation

Warren Buffett Piles on SPACs and CF Finance Lowers Deal Valuation
It was a bad day for SPACs as Warren Buffett piled on SPACs; CF Finance lowered their deal valuation with AEye; and today s MAAC deal had no pop.
Author:
May 3, 2021

Stocks were mixed on Monday, the S&P500 was up / NASDAQ down, though this morning s SPAC M&A deal (MAAC) once again underperformed. MAAC closed up just 0.9% and below NAV at $9.95 marking yet another disappointing day-1 pop for newly announced SPAC M&A.
Warren Buffett and Charlie Munger held Berkshire Hathaway s much watched virtual annual meeting over the weekend, and one of the talks of the town today (aside from naming his CEO successor) was his view on killer SPACs: ....

Warren Buffett , Charlie Munger , Aeye Inc , Hera Acquisition Corp Pre , Mudrick Capital Acquisition Corporation , Churchill Capital Corp , Cf Finance Acquisition Corp , Sciences Acquisition Corp Iv Pre , Cm Life Sciences Ii Inc , Fintech Acquisition Corp , Roivant Sciences , Vesper Healthcare Acquisition Corp , Berkshire Hathaway , Innoviz Technologies Ltd , Growth Corp , Churchill Capital Corp Vi Pre , Ouster Inc , Luminar Technologies Inc , Graf Industrial Corp , Deerfield Healthcare Technology Acquisitions Corp , Capital Hedosophia Holdings Corp , Ts Innovation Acquisitions Corp , Roivant Sciences Public , Acquisition Corp , Arclight Clean Transition Corp , Interprivate Acquisition Corp ,

Roivant's move to go public reveals just how much its drug strategy has changed

Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy. ....

New York , United States , Sumitomo Dainippon Pharma , Vivek Ramaswamy , Matthew Gline , Montes Archimedes Acquisition Corp , Roivant Sciences , Fidelity Management Research Company , Softbank Group , Switzerland Based Roivant , Montes Archimedes , Sio Gene , Silicon Therapeutics , Fidelity Management , Research Company , Eventide Asset Management , Suvretta Capital , Palantir Technologies , Viking Global Investors , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , விவேக் ராமசாமி , மேத்யூ கிளினே , மான்டஸ் ஆர்க்கிமிடீஸ் கையகப்படுத்தல் கார்ப் , றொய்வன்ட் அறிவியல் , நம்பகத்தன்மை மேலாண்மை ஆராய்ச்சி நிறுவனம் ,

Roivant valued at $7B in blank-check merger, bucking SPAC slowdown

Dive Brief:
Roivant Sciences, an unusual holding company with roughly a dozen biotech subsidiaries, will go public through a merger with a blank-check entity in a deal that values the company at $7.3 billion.
Roivant will get $611 million in cash by merging with Montes Archimedes Acquisition Corp., a special purpose acquisition company, or SPAC, formed by Patient Square Capital. That figure includes $411 million already in a Montes Archimedes Trust and a commitment by Patient Square and other investors to buy $200 million in Roivant stock at $10 apiece.
The agreement will leave Roivant, whose subsidiaries have had both high-profile successes as well as failures, with $2.3 billion in cash upon going public. The deal, one of the larger SPAC mergers in biotech, comes amid signs the boom in such deals may be waning. Returns are down, while many SPACs are in competition for takeover targets. Federal oversight, meanwhile, appears to be increasing. ....

Sumitomo Dainippon Pharma , Vivek Ramaswamy , Matthew Gline , Axovant Sciences , Exchange Commission , Roivant Sciences , Puretech Health , Montes Archimedes Acquisition Corp , Montes Archimedes , Centessa Pharmaceuticals , Health Sciences Acquisition Corp , Dive Brief , Patient Square , Montes Archimedes Trust , Sumitomo Dainippon , Sio Gene Therapies , Arbutus Biopharma , Sciences Acquisition , Financial Times , விவேக் ராமசாமி , மேத்யூ கிளினே , பரிமாற்றம் தரகு , றொய்வன்ட் அறிவியல் , மான்டஸ் ஆர்க்கிமிடீஸ் கையகப்படுத்தல் கார்ப் , மான்டஸ் ஆர்க்கிமிடீஸ் , ஆரோக்கியம் அறிவியல் கையகப்படுத்தல் கார்ப் ,

(MAAC), (ABUS) - Roivant Sciences Gets SPAC Deal: What To Expect From This BioPharma, Health Technology Company

Share:
A drug discovery company with ownership stakes in several public and private biopharmaceutical companies is going public with a SPAC deal announced Monday morning.
The SPAC Deal: Roviant Sciences announced a SPAC deal with
Montes Archimedes Acquisition Corp (NASDAQ: MAAC). The deal values the company at an enterprise value of $5 billion.
A $200 million PIPE is backed by companies including Softbank Group Corp., Fidelity Management & Research Co., Sumitomo Dainippon Pharma and
Palantir Technologies Inc (NYSE: PLTR).
Shares of the new company will trade as ROIV on the Nasdaq with an anticipated closing date in the third quarter.
A percentage of current ownership shares will have a three-year lock-up and earn-outs based on $15 and $20 price points. Current Montes Archimedes acquisition shareholders will own 5.6% of the company after the merger. ....

Sumitomo Dainippon Pharma , Sumitomo Dainippon , Fidelity Management Research Co , Softbank Group Corp , Sio Gene Therapies Inc , Arbutus Biopharma Corp , Montes Archimedes Acquisition Corp , Immunovant Inc , Roviant Sciences , Palantir Technologies Inc , Fidelity Management , Montes Archimedes , Silicon Therapeutics , நம்பகத்தன்மை மேலாண்மை ஆராய்ச்சி இணை , சாப்ட் பேங்க் குழு கார்ப் , சிோ கீந் சிகிச்சைகள் இன்க் , மான்டஸ் ஆர்க்கிமிடீஸ் கையகப்படுத்தல் கார்ப் , நம்பகத்தன்மை மேலாண்மை , மான்டஸ் ஆர்க்கிமிடீஸ் , சிலிக்கான் சிகிச்சை ,